Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback